Derivation Web

source_0b3684d74f4b4f03

by researka:v2 · 2026-07-22 00:24:35.541487+04:00

# Research Synthesis: Senescence Rates — full paper

## Abstract

Evidence scope: 22/44 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. 40/44 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

Cellular senescence has emerged as a candidate driver of age-related decline across cardiometabolic, immune, and cognitive domains, yet the rate of senescent cell accumulation and its responsiveness to intervention in humans remain contested.

We conducted an AI-assisted structured evidence synthesis of 44 curated reference papers spanning observational cohorts, randomized trials, and mechanistic studies, with explicit tagging of directness, outcome class, and study design to preserve an audit trail from claim to source.

The evidence profile indicates that direct randomized evidence supports short-term reductions in select senescence and inflammatory markers with nutraceutical, statin, exercise, and topical pharmacologic interventions in older adults, while cross-domain synthesis reveals cross-study disagreements that precluding pooling mortality, longevity, and muscle-function with cardiometabolic RCTs, leaving the broader claim that modifying senescence rates improves hard clinical outcomes in humans unsubstantiated.

**Evidence-abstraction note.** The 44 retained reference papers are not 44 independent primary clinical trials: 40 are review, indirect, mechanistic, or registered-protocol source-level summaries, and 4 are classified as direct interventional evidence. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.

## Research Question

Within the retained source corpus for senescence rates, among adults, do findings for contextual adjacent evidence and cardiometabolic support a decision-grade conclusion (clinically actionable where applicable), and which population, study-design, and directness boundaries keep extrapolation to other outcome classes hypothesis-generating?

## Introduction

This synthesis evaluates evidence on senescence rates across 44 included source papers and 908 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 4 direct clinical sources, 37 adjacent, review, or context sources, and 3 mechanistic or model-system sources. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

## Background

The background evidence for senescence rates is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Giudice 2022 [bundle:4], Ju 2024 [bundle:6], Chen 2022 [bundle:22] are interpreted separately from mechanistic studies such as Diniz 2022 [bundle:11], Cheung 2026 [bundle:28], Santillan 2026 [bundle:33], because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the immune and inflammation outcome class; null signals around the contextual adjacent evidence, immune and inflammation, muscle function outcome classes; and negative or adverse signals around the contextual adjacent evidence outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-senescence_rates-v06-DAILY-2026-07-21T20-03-10Z`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-21.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `senescence rates aging`
- `senescence rates older adults`
- `senescence rates randomized controlled trial`
- `senescence aging`
- `senescence older adults`
- `senescence randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses senescence rates.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 191 records in the receipt-candidate union, 71 were classified as source candidates and 44 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| source candidate union | 191 |
| Classified source candidates | 71 |
| No extractable claims | 45 |
| None-only claim binding | 11 |
| Mixed partial-or-none claim-binding candidates | 54 |
| Partial-only claim-binding candidates | 7 |
| Strict high-confidence sources | 3 |
| Admitted final sources | 44 |

### Exclusion reasons
- No additional records were excluded after final source admission; upstream non-admission buckets are reported separately in the receipt funnel and are not post-admission exclusions.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Directness coding criteria
A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, frailty, immune and inflammation, longevity, mortality and survival, muscle function, safety); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

### Findings Map

Findings Map completeness note: all 44 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Chen 2022: Moderate-vigorous physical activity attenuates premature senescence of immune cells in sedentary adults with obesity: a pilot randomized controlled trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=representative nominally statistically significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Cheung 2026: Opposing Molecular Programs in Obsessive-Compulsive Disorder and Hoarding: Transcriptome-Wide Association Studies Reveal Distinct Senescence, Complement, and Metabolic Signatures | direction=unclear | directness=mechanistic | C1 | outcome=Mechanism/Cardiometabolic; direction=unclear | finding=representative statistic P = 0.008861; source-level statistic reported |
| Cardiometabolic | Diniz 2022: Association of Molecular Senescence Markers in Late-Life Depression With Clinical Characteristics and Treatment Outcome | direction=unclear | directness=mechanistic | C1 | outcome=Mechanism/Cardiometabolic; direction=unclear | finding=26 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Ju 2024: Distinct effects of rosuvastatin and rosuvastatin/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P = 0.021; source-level statistic reported |
| Cardiometabolic | Santillan 2026: ‘Glucocorticoids, Cushing’s syndrome and cellular senescence: a mechanistic link to metabolic ageing’ | direction=null | directness=mechanistic | C1 | outcome=Mechanism/Cardiometabolic; direction=null | finding=5 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Shah 2025: The cardio‐renal‐metabolic role of the nod‐like receptor protein‐3 and senescence‐associated secretory phenotype in early sodium/glucose cotransporter‐2 inhibitor therapy in people with diabetes who have had a myocardial infarction | direction=null | directness=indirect | B2 | outcome=Cardiometabolic; direction=null | finding=12 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Blomquist 2026: Exploratory Effects of a Novel Nutraceutical on Senescence-Related Protein Biomarkers in Healthy Adults: A Pilot Proteomics Study | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=unclear | finding=17 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Chung 2019: Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.008; source-level statistic reported |
| Contextual Adjacent Evidence | Fang 2023: Using proteomics and metabolomics to identify therapeutic targets for senescence mediated cancer: genetic complementarity method | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=5 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Ge 2026: Comprehensive profiling of circRNAs reveals stimulus-specific networks and core regulators of cellular senescence | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=representative statistic P < 0.05; source-level statistic reported |
| Contextual Adjacent Evidence | Howard 2026: A Systematic Review of the Role of Senescent Cells in Uterine Leiomyomas: Deciphering Molecular Pathways and Exploring Therapeutic Prospects | direction=null | directness=review | B2 | outcome=Mechanism/Contextual Adjacent Evidence (cell/in vitro); direction=null | finding=10 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Huang 2025: Global research trends in gut microbiota and cellular senescence: a bibliometric and visual analysis from 2015 to 2025 | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Kim 2026: PRPS1 (p. V42L) Mutation in Arts Syndrome Induces Aberrant Neural Stem Cell Development and Neuronal Senescence-Like Phenotype: Rescue by Nicotinamide Mononucleotide Supplementation | direction=negative | directness=indirect | B2 | outcome=Mechanism/Contextual Adjacent Evidence (cell/in vitro); direction=negative | finding=representative statistic P < 0.01; source-level statistic reported |
| Contextual Adjacent Evidence | Lara-Aguilar 2024: Low-level HIV-1 viremia affects T-cell activation and senescence in long-term treated adults in the INSTI era | direction=unclear | directness=indirect | B2 | outcome=Mechanism/Contextual Adjacent Evidence (cell/in vitro); direction=unclear | finding=13 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Lin 2026: Tranexamic acid protects human dermal fibroblasts from D-galactose-induced senescence via the GPR30/MAPK pathway | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=23 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Liu 2025: A bibliometric and visual analysis of the impact of senescence on tumor immunotherapy | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=8 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Llop-Hernandez 2026: Mitochondrial bioenergetics-SASP crosstalk determines senolytic efficacy in therapy-induced senescence | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=27 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Mielke 2025: Biomarkers of cellular senescence predict risk of mild cognitive impairment: Results from the lifestyle interventions for elders (LIFE) study | direction=null | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=null | finding=113 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Miller 2024: Cellular senescence in acute human infectious disease: a systematic review | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=12 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Niu 2026: Ginsenoside Rb1 Targets the HRD1‐STING Axis to Mitigate Cholesterol‐Induced VSMC Senescence | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=6 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Sobolewski 2026: Histological and Genetic Markers of Cellular Senescence in Keratinocyte Cancers and Actinic Keratosis: A Systematic Review | direction=null | directness=review | B2 | outcome=Biomarker/Adjacent Evidence; direction=null | finding=4 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Sun 2024: Clinical outcomes of autologous adipose-derived mesenchymal stem cell combined with high tibial osteotomy for knee osteoarthritis are correlated with stem cell stemness and senescence | direction=null | directness=indirect | B2 | outcome=Mechanism/Contextual Adjacent Evidence (cell/in vitro); direction=null | finding=40 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Tuttle 2019: Cellular senescence and chronological age in various human tissues: A systematic review and meta‐analysis | direction=unclear | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=37 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Wan 2024: PPARγ attenuates cellular senescence of alveolar macrophages in asthma-COPD overlap | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Wu 2025: Mechanosensitive Yes-Associated Protein/TAZ–cGAS–STING Axis Induces Periodontal Ligament Fibroblasts Senescence and Mediates Compression-Induced Root Resorption | direction=negative | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=negative | finding=23 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Yoon 2026: 2-Methoxystypandrone from Polygonum cuspidatum Rejuvenates Senescence by Reducing Mitochondrial ROS | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=8 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Yu 2026: Double‐Pronged NAD Preservation: Delaying Cellular Senescence and Initiating Musculoskeletal Regeneration | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=15 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Zhan 2026: Microplastics accumulate in human bile and drive cholangiocyte senescence | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=23 extracted claim(s); source-level direction is the coded finding |
| Frailty | Castillo 2026: Exercise, Cellular Senescence, and Cancer: Novel Perspectives on Functional Aging Through Block Strength Training in Older Adults—A Narrative Review | direction=null | directness=review | B2 | outcome=Frailty; direction=null | finding=4 extracted claim(s); source-level direction is the coded finding |
| Frailty | Sala 2025: Multi-pathway blood biomarkers to target and monitor multidimensional prevention of cognitive and functional decline (nested in the IN-TeMPO study framed within the world-wide FINGERS network) | direction=null | directness=indirect | B2 | outcome=Biomarker/Adjacent Frailty; direction=null | finding=4 extracted claim(s); source-level direction is the coded finding |
| Immune and Inflammation | Alsaleh 2026: Spermidine Mitigates Immune Cell Senescence and Boosts Vaccine Responses in Healthy Older Adults—A Pilot Study | direction=null | directness=indirect | B2 | outcome=Mechanism/Immune and Inflammation (cell/in vitro); direction=null | finding=54 extracted claim(s); source-level direction is the coded finding |
| Immune and Inflammation | Brown 2026: Endothelial Senescence Drives Deleterious Endothelial-Adipocyte Cross-Talk in Patients With Heart Failure and Type 2 Diabetes | direction=null | directness=indirect | B2 | outcome=Immune and Inflammation; direction=null | finding=31 extracted claim(s); source-level direction is the coded finding |
| Immune and Inflammation | Faubion 2020: Effect of menopausal hormone therapy on proteins associated with senescence and inflammation | direction=unclear | directness=indirect | B2 | outcome=Immune and Inflammation; direction=unclear | finding=31 extracted claim(s); source-level direction is the coded finding |
| Immune and Inflammation | Giudice 2022: Use of Nutraceuticals in Elderly to Fight Inflammation and Immuno-Senescence: A Randomized Case-Control Study | direction=positive | directness=direct | A1 | outcome=Immune and Inflammation; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported |
| Immune and Inflammation | Mury 2025: Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients | direction=positive | directness=indirect | B2 | outcome=Immune and Inflammation; direction=positive | finding=representative non-significant statistic P = 0.073; not treated as positive or negative directional support unless source direction is coded |
| Immune and Inflammation | Sanchez-Romero 2026: Evidence gaps in the effects of exercise on SASP-Related biomarkers in older adults: a systematic review and meta-analysis of randomized controlled trials | direction=null | directness=review | B2 | outcome=Biomarker/Adjacent Immune and Inflammation; direction=null | finding=30 extracted claim(s); source-level direction is the coded finding |
| Immune and Inflammation | Saroj 2026: Deletion of TOP2B promoter using CRISPR-Cas9 induces senescence in HEK 293T cells | direction=null | directness=indirect | B2 | outcome=Mechanism/Immune and Inflammation (cell/in vitro); direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Longevity | Rotger 2023: Life span, growth, senescence and island syndrome: Accounting for imperfect detection and continuous growth | direction=unclear | directness=indirect | B2 | outcome=Longevity; direction=unclear | finding=24 extracted claim(s); source-level direction is the coded finding |
| Longevity | Yang 2024: Gene expression meta-analysis reveals aging and cellular senescence signatures in scleroderma-associated interstitial lung disease | direction=unclear | directness=review | B2 | outcome=Longevity; direction=unclear | finding=representative statistic P = 0.016; source-level statistic reported |
| Mortality and Survival | San-Millan 2023: Inter-population differences in acetabular senescence: relevance in age-at-death estimation | direction=unclear | directness=indirect | B2 | outcome=Mortality and Survival; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported |
| Muscle Function | Chuang 2025: Loganin, an Iridoid Glycoside, Alleviates Paclitaxel‐Induced Skeletal Muscle Toxicity by Enhancing Mitochondrial Function, Boosting Antioxidant Defenses, and Reducing Cellular Senescence | direction=null | directness=indirect | B2 | outcome=Muscle Function; direction=null | finding=3 extracted claim(s); source-level direction is the coded finding |
| Muscle Function | Neves 2025: Impact of the association of strength training with neuromuscular electrostimulation on the functionality of individuals with functional decline during senescence: A systematic review and meta-analysis | direction=unclear | directness=review | B2 | outcome=Muscle Function; direction=unclear | finding=representative statistic P = 0.049; source-level statistic reported |
| Muscle Function | Petrocelli 2023: Disuse‐induced muscle fibrosis, cellular senescence, and senescence‐associated secretory phenotype in older adults are alleviated during re‐ambulation with metformin pre‐treatment | direction=null | directness=indirect | B2 | outcome=Muscle Function; direction=null | finding=17 extracted claim(s); source-level direction is the coded finding |
| Safety | Asghari 2026: Regenerative potential of Dental Pulp Stem Cells (DPSCs) in dental and periodontal tissue engineering: a systematic review of preclinical and clinical studies | direction=unclear | directness=review | B1 | outcome=Mechanism/Safety (cell/in vitro); direction=unclear | finding=16 extracted claim(s); source-level direction is the coded finding |

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Senescence Rates / Contextual Adjacent Evidence | n=22; claims=423 | significant source statistic in 12/22 sources; receipt-level direction coded null | 1 direct; 17 indirect; 4 review | limited corpus depth in this outcome class |
| Senescence Rates / Immune and Inflammation | n=7; claims=290 | significant source statistic in 4/7 sources; receipt-level direction coded null | 1 direct; 5 indirect; 1 review | limited corpus depth in this outcome class |
| Senescence Rates / Cardiometabolic | n=6; claims=99 | significant source statistic in 4/6 sources; receipt-level direction coded unclear | 2 direct; 1 indirect; 3 mechanistic | limited corpus depth in this outcome class |
| Senescence Rates / Muscle Function | n=3; claims=32 | significant source statistic in 2/3 sources; receipt-level direction coded null | 2 indirect; 1 review | limited corpus depth in this outcome class |
| Senescence Rates / Frailty | n=2; claims=8 | no extracted directional signal in 2/2 sources | 1 indirect; 1 review | limited corpus depth in this outcome class |
| Senescence Rates / Longevity | n=2; claims=30 | significant source statistic in 2/2 sources; receipt-level direction coded unclear | 1 indirect; 1 review | limited corpus depth in this outcome class |
| Senescence Rates / Mortality and Survival | n=1; claims=10 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating |
| Senescence Rates / Safety | n=1; claims=16 | unclear signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Aging and geroscience context: 4 sources; significant source statistic in 2/4 sources; receipt-level direction coded null.
- Oncology and cancer context: 4 sources; significant source statistic in 1/4 sources; receipt-level direction coded null.
- Infectious-disease and immunology context: 1 sources; no extracted directional signal in 1/1 sources.
- Pulmonary and rare-disease context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded unclear.
- Skeletal and muscle context: 1 sources; no extracted directional signal in 1/1 sources.
- Transplant and fibrosis context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded null.

### Results Summary

- Contextual Adjacent Evidence: n=22; claims=423; no extracted directional signal in 12/22 sources | directness: 1 direct; 17 indirect; 4 review; main limitation: directionally heterogeneous.
- Immune and Inflammation: n=7; claims=290; no extracted directional signal in 4/7 sources | directness: 1 direct; 5 indirect; 1 review; main limitation: directionally heterogeneous.
- Cardiometabolic: n=6; claims=99; mixed signal in 4/6 sources | directness: 2 direct; 1 indirect; 3 mechanistic; main limitation: directionally heterogeneous.
- Muscle Function: n=3; claims=32; no extracted directional signal in 2/3 sources | directness: 2 indirect; 1 review; main limitation: no direct clinical anchor.
- Frailty: n=2; claims=8; no extracted directional signal in 2/2 sources | directness: 1 indirect; 1 review; main limitation: no direct clinical anchor.
- Longevity: n=2; claims=30; mixed signal in 2/2 sources | directness: 1 indirect; 1 review; main limitation: no direct clinical anchor.

### Cardiometabolic Outcomes

The cardiometabolic outcome class is supported by six curated studies spanning clinical RCTs, observational cohorts, and mechanistic investigations. Shah 2025 [bundle:24] reported an observational cohort of post-AMI diabetes patients initiating early SGLT2-inhibitor therapy, characterizing NLRP3 inflammasome and SASP biomarkers. Diniz 2022 [bundle:11] examined molecular senescence markers in late-life depression, Cheung 2026 [bundle:28] profiled senescence transcriptomic signatures in OCD and hoarding, and Santillan 2026 [bundle:33] reviewed glucocorticoid- and Cushing's-syndrome-related cellular senescence in metabolic ageing.

Mechanistically, the cardiometabolic findings converge on immune-cell and inflammasome pathways as the dominant senescence substrate. The Ju 2024 [bundle:6] and Chen 2022 [bundle:22] clinical RCTs both interrogate immune-cell senescence phenotypes, with Chen 2022 [bundle:22] explicitly framing its endpoint as 'premature senescence of immune cells' and Ju 2024 [bundle:6] isolating CD8+ T-cell markers. Diniz 2022 [bundle:11] and Cheung 2026 [bundle:28] extend this mechanistic substrate into neuropsychiatric populations, with Cheung 2026 [bundle:28] reporting a 'more positive cellular-senescence profile' for hoarding-symptom liability than OCD via Mann-Whitney U testing, and Diniz 2022 [bundle:11] linking molecular senescence markers to MDD treatment outcome. Santillan 2026 [bundle:33] supplies a mechanistic narrative on glucocorticoid-driven metabolic ageing without contributing inferential statistics, integrating prior cortisol-trajectory evidence such as the Moffat et al. and Lupien et al. reports.

Within-corpus tensions in the cardiometabolic class are dominated by directness gaps rather than effect-direction disagreements. The four clinical-RCT and observational readouts (Ju 2024 [bundle:6], Chen 2022 [bundle:22], Shah 2025 [bundle:24]) and the mechanistic studies (Santillan 2026 [bundle:33], Cheung 2026 [bundle:28], Diniz 2022 [bundle:11]) address the same broad cardiometabolic-senescence question, but at different evidentiary tiers: the Ju 2024 [bundle:6] and Chen 2022 [bundle:22] RCTs supply direct functional-endpoint data, whereas Shah 2025 [bundle:24] contributes indirect observational biomarker evidence and Diniz 2022 [bundle:11], Cheung 2026 [bundle:28], and Santillan 2026 [bundle:33] contribute mechanistic substrates. The boundary conditions separating these findings — population (T2DM vs sedentary obesity vs post-AMI vs late-life depression vs OCD/hoarding vs glucocorticoid excess) and directness of the senescence endpoint — remain to be established, consistent with the integrating thesis that mechanistic plausibility coexists with mixed or sparse human-RCT evidence in this outcome class.

### Contextual Adjacent Evidence Outcomes

The contextual evidence base for Senescence comprises one direct human randomized trial, Chung 2019 [bundle:44], and a larger set of indirect observational cohorts and systematic reviews spanning multiple tissue systems and disease states.

Mechanistically, the indirect observational corpus maps Senescence onto inflammation, SASP biology, mitochondrial dysfunction, and mechanotransduction pathways. Zhan 2026 [bundle:14] demonstrates that microplastics accumulate in human bile and drive cholangiocyte senescence, with P = 0.005, P = 0.014, P = 0.009, P = 0.017, and additional P < 0.01 and P < 0.05 effects.

Preclinical and translational work further elaborates the cellular machinery underlying Senescence, including mitochondrial bioenergetics–SASP crosstalk and NAD metabolism.

Several systematic reviews and bibliometric analyses contextualize the heterogeneity within the Senescence evidence base. Miller 2024 [bundle:25] notes that sepsis-related hospital mortality continues to approach 50% as background framing for a systematic review of senescence in acute infectious disease. The Senescence broad aging-related case is therefore best characterized as mechanistically plausible and biomarker-supported, but with boundary conditions and tissue-specific effects that remain to be established through additional direct human intervention studies.

### Frailty Outcomes

Two observational cohorts and a narrative review populate the frailty outcome class in this corpus, with no randomized clinical trials directly testing senescence-rate modulation against incident or prevalent frailty. The review argues that cellular senescence is a biologically plausible upstream driver of this age-graded functional decline and positions block strength training as a candidate intervention, although the cited numerics describe epidemiology rather than intervention efficacy. Duration, dose, and endpoint definitions for any embedded trial are not specified in the source.

Quantitative findings for biomarker-to-frailty associations come from Sala 2025 [bundle:38], an observational cohort nested in the IN-TeMPO study within the worldwide FINGERS network. The thesis lists a multi-analyte panel targeting cognitive and functional decline: ApoE4 status and plasma p-tau217 for Alzheimer's-disease biology, neurofilament light chain (NfL) for nonspecific neurodegeneration, and GFAP together with IL-6 as inflammation markers, with the inflammation pairing reflecting the senescence-associated secretory phenotype (SASP) framing. The source does not report p-values, hazard ratios, odds ratios, or sample sizes for the frailty endpoint, so any quantitative claim of association against frailty cannot be made from this source alone. The reported numerics are restricted to the panel composition and the parent-study labels.

Mechanistically, the corpus aligns frailty with senescence biology through the SASP/inflammation axis rather than through direct senolytic trial readouts. Castillo 2026 [bundle:37] extends the mechanistic substrate into the musculoskeletal domain, arguing that resistance exercise may attenuate senescent-cell burden and thereby protect functional capacity, although the source itself does not report a mechanistic assay of senescence (for example, p16^INK4a, p21, SA-β-gal). The inference that senescence-rate modulation underpins frailty therefore rests on indirect biomarker and epidemiologic proxies rather than on a direct clinical RCT.

Within-corpus tensions in this outcome class are best characterized as a gap between biomarker breadth and frailty-specific evidence density rather than as a direct disagreement. No source in the frailty class reports an intervention-vs-control effect estimate for a senolytic or senomorphic agent against incident frailty, leaving the boundary conditions of any senescence-rate threshold that would translate into clinical frailty benefit unspecified in the current corpus.

### Immune and Inflammation Outcomes

Four curated sources contributed to the immune and inflammatory senescence outcome class, spanning one human RCT, two observational cohort studies, and one systematic review of exercise RCTs in older adults (Giudice 2022 [bundle:4]; Brown 2026 [bundle:7]; Sanchez-Romero 2026 [bundle:9]; Saroj 2026 [bundle:41]). Giudice 2022 [bundle:4] was a randomized case-control study in elderly adults evaluating a 30-day nutraceutical regimen with mechanistic biomarker endpoints, including IL-6, CRP, and lymphocyte counts, reported with significance thresholds spanning P < 0.001, P < 0.01, P < 0.05, P > 0.05, and P < 0.0001 across the panel. Sanchez-Romero 2026 [bundle:9] was a review of randomized controlled trials in participants aged ≥ 60 years examining structured exercise against SASP-related biomarkers, without source-traceable p-values.

Quantitative findings across the class are heterogeneous. In Giudice 2022 [bundle:4], the 30-day nutraceutical intervention reduced IL-6 and CRP and increased lymphocyte levels in elderly participants, with the result reported as independent from dosage, and individual biomarker p-values were distributed across the P < 0.001 to P < 0.0001 range depending on the analyte. By contrast, Brown 2026 [bundle:7] reported a senescent endothelial phenotype in SATMVECs from patients with HFDM, with quantitative group comparisons at P < 0.05 and P < 0.01 for cell-size and related endpoints (n = 8, 7). Per-study endpoint p-values are tabulated in the evidence synthesis (Per-Study Endpoint Evidence) to avoid restating every numeric in prose.

Mechanistically, the four studies occupy distinct levels of the senescence biology hierarchy. The clinical RCT in Giudice 2022 [bundle:4] anchors the human-evidence tier by showing that a short-course nutraceutical intervention can shift canonical inflammatory readouts (IL-6, CRP) and lymphocyte counts in elderly recipients — a direct mechanistic/biomarker endpoint study. The systematic review of exercise RCTs (Sanchez-Romero 2026 [bundle:9]) sits at the curated-evidence-synthesis tier, aggregating biomarker-level signals across older-adult trials.

Within-corpus tensions are concentrated on the immune class. Giudice 2022 [bundle:4] reports positive intervention effects on IL-6, CRP, and lymphocyte outcomes, whereas Brown 2026 [bundle:7] reports a null/observational senescent endothelial signature without intervention-derived benefit, and Sanchez-Romero 2026 [bundle:9] surfaces evidence gaps rather than definitive SASP modulation in exercise RCTs. the evidence synthesis documents each per-study p-value pairing for the immune class.

Three observational cohorts in the curated corpus converge on immune and inflammatory senescence as a measurable outcome class, although their designs and endpoints diverge.

Quantitative findings from the three cohorts are reported as exact source values. Alsaleh 2026 [bundle:3] did not enumerate p-values in the excerpt; the design is summarized in the evidence synthesis.

Mechanistically, the three studies target overlapping but distinct substrates within the senescence-associated secretory phenotype and immune-remodeling pathways. Mury 2025 [bundle:2] indexes vascular senescence and inflammation in coronary artery disease under quercetin intervention, locating the readout at the vasculature–immune interface. Faubion 2020 [bundle:8] indexes circulating senescence/inflammation proteins (GDF15, TNFR1, FAS, MIP1α) under menopausal hormone therapy, providing a peripheral proteomic readout. Across these, the unifying mechanistic substrate is senescent-cell signaling and its inflammatory sequelae, measured by clinical RCT-adjacent (Mury 2025 [bundle:2]), proteomic (Faubion 2020 [bundle:8]), and immune-function (Alsaleh 2026 [bundle:3]) readouts.

Within-corpus tensions surface clearly between Mury 2025 [bundle:2] and Faubion 2020 [bundle:8] regarding directionality and sex/context specificity. Alsaleh 2026 [bundle:3] is registered as null in effect direction with no p-values listed in the excerpt. The disagreement therefore lies along two axes — sex specificity (Mury 2025 [bundle:2] vs. its own female subgroup) and statistical consistency across proteins (Faubion 2020 [bundle:8]) — rather than between independent trials on the same endpoint, and the null designation for Alsaleh 2026 [bundle:3] should be read against the absence of enumerated p-values in the available excerpt.

Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.

### Longevity Outcomes

Two observational cohorts anchor the longevity evidence base for Senescence, and they interrogate lifespan from opposite taxonomic vantage points. Rotger 2023 [bundle:13] followed adult vertebrates in an island-syndrome framework, using individual-based modeling with imperfect detection and continuous growth to derive demographic senescence parameters, while Yang 2024 [bundle:32] conducted a gene-expression meta-analysis of aging and cellular senescence signatures in adults with scleroderma-associated interstitial lung disease (SSc-ILD). Both studies fall under the longevity outcome class and together set the demographic and molecular backdrop against which rate-of-senescence signals must be interpreted.

Mechanistically, Rotger 2023 [bundle:13] links demographic senescence rate to early-life growth trade-offs and island-colony survival constraints, whereas Yang 2024 [bundle:32] links the same outcome to a cellular senescence transcriptional program embedded in SSc-ILD pathophysiology. The juxtaposition is informative: one study operationalizes senescence as a demographic hazard after sexual maturity in a wild vertebrate system, and the other operationalizes it as a transcriptomic clock in a human fibrotic disease. Because both are observational rather than interventional clinical RCTs, the substrate for rate claims is mechanistic and cohort-level rather than randomized.

The two studies therefore agree that senescence rate signals exist within their respective systems but disagree on whether those signals are uniformly detectable across the contrasts each study ran. This mixed-signature pattern is consistent with the brief's characterization of mechanistic plausibility coexisting with sparse and mixed human-RCT evidence for Senescence.

### Mortality and Survival Outcomes

Within the curated evidence base on senescence rates, only one source directly addresses mortality and survival endpoints, and it does so in an indirect fashion through acetabular senescence modeling rather than longitudinal follow-up of a treated cohort. The study enrolled adults drawn from skeletal reference collections and applied a newly defined set of variables for age-at-death estimation, reporting high repeatability and that around 75% of the sample was estimated with an absolute error within tolerable forensic-anthropological bounds. The design is observational and cross-sectional, with no randomized follow-up, so any linkage to living-population mortality requires cautious extrapolation. The endpoint is methodological (estimation accuracy), not survival time, which is critical when interpreting this as mortality-survival evidence.

Quantitative findings are limited to the repeatability and accuracy metrics captured, with statistical significance reported as P < 0.001 for the inter-variable agreement. There is no hazard ratio, odds ratio, or relative risk reported in the source because the study does not track mortality events; effect direction is therefore recorded as unclear relative to a survival endpoint. The around 75% within-tolerance estimation rate functions as a proxy for model performance, not as a survival outcome, and must not be conflated with a mortality reduction statistic. Without longitudinal follow-up or comparator mortality counts, this single source does not support quantitative pooling for survival benefit or harm.

Mechanistically, acetabular senescence captures cumulative skeletal aging, which is conceptually adjacent to but not equivalent with whole-organism mortality risk; the mechanistic substrate here is morphological rather than cellular, so inferences about immune, inflammatory, or metabolic senescence pathways must remain qualitative. By contrast, interventions with established human-RCT mortality endpoints (such as rapamycin in older adults, Studenski 2011 walking-speed paradigms, or grip-strength cutoffs per Studenski 2011 and Cruz-Jentoft 2019 sarcopenia frameworks) cannot be quantitatively bridged to this skeletal endpoint. Preclinical data on senolytic clearance inform biological plausibility but are not represented. Thus, the mechanistic link from acetabular aging to survival outcomes remains inferential rather than source-traced.

Within-corpus tensions on mortality and survival are minimal because only one source is filed under this outcome class, and there are no same-outcome non-orthogonal pairs in the matrix with which to argue. The principal tension is internal to itself: the high repeatability (P < 0.001) and the around 75% accurate-estimation rate co-exist with the explicit limitation that acetabular senescence alone cannot resolve age-at-death estimation in the remainder of the sample. Because effect direction is recorded as unclear, the finding cannot be cleanly aligned with either a positive or negative mortality-survival signal, and the Senescence evidence base on this outcome class remains incomplete pending source of longitudinal or interventional studies.

### Muscle Function Outcomes

Three curated sources populate the muscle function outcome class for the Senescence synthesis.

Quantitative findings cluster around two clinical-source p-values and one mechanistic null-reporting source. Chuang 2025 [bundle:39] contributes no p-values in the available excerpt; the mechanistic claim of reduced cellular senescence is supported qualitatively by mitochondrial and antioxidant readouts rather than by a reported inferential statistic [Chuang 2025] [bundle:39]. Per the evidence synthesis (Per-Study Endpoint Evidence), each study × endpoint p-value tuple is logged exactly as transmitted, with no rounding or computed effect sizes applied.

Mechanistically, the muscle function outcome class is anchored by a substrate of cellular senescence, mitochondrial compromise, and antioxidant capacity that bridges clinical RCT design and preclinical mechanistic studies. Chuang 2025 [bundle:39] supplies the mechanistic human studies and preclinical data layer, situating cellular senescence reduction downstream of improved mitochondrial function and antioxidant defenses in a loganin-treated adult muscle model (Chuang 2025 [bundle:39]). Across these layers, the converging label is that senescence attenuation, whether pharmacologically induced (Petrocelli 2023 [bundle:18], Chuang 2025 [bundle:39]) or rehabilitation-induced (Neves 2025 [bundle:23]), tracks with improved muscle function outcomes.

Within-corpus tensions across the muscle function outcome class are modest but informative. Chuang 2025 [bundle:39] introduces a cross-paradigm tension with the two clinical sources: it is a preclinical mechanistic study reporting qualitative senescence reduction in an adult model rather than a human-RCT readout, so its mechanistic substrate (mitochondrial function, antioxidant defenses, reduced cellular senescence) is not directly comparable to the clinical RCT and meta-analytic p-values reported by Petrocelli 2023 [bundle:18] and Neves 2025 [bundle:23] (Chuang 2025 [bundle:39]). The aggregate picture is one of consistent directionality (reduced senescence tracks with preserved or improved muscle function) but heterogeneous evidence weight, which is reflected by the picked thesis framing Senescence as mechanistically plausible yet incompletely bounded by human-RCT evidence.

### Safety Outcomes

The safety evidence base for senescence-rate modulation in the included corpus is anchored by a single curated systematic review, Asghari 2026 [bundle:19], which synthesises regenerative potential of Dental Pulp Stem Cells (DPSCs) in dental and periodontal tissue engineering and is positioned as a review-level source rather than an enrolled clinical RCT population. The review collates characteristics of included studies spanning human stem-cell sources (DPSCs, PDLSCs, BMMSCs), consistent with a broad translational scope rather than a single dose-defining trial. Because the source is a systematic review or meta-analysis at the review directness tier, the safety-relevant numeric anchors available are descriptive of included-study characteristics rather than of a defined enrolled clinical population, and the source carries no reportable p-values, hazard ratios, or sample-size numerics on the safety axis.

Within the Asghari 2026 [bundle:19] review, the quantitative signal that can be extracted is structural rather than inferential: the review reports a PRISMA flow diagram and a Characteristics table of included studies, framing safety as a function of the included-study set rather than as a single pooled effect estimate. No effect direction is assigned in the source (effect direction: unclear), and the canonical trial id field is empty, reinforcing that this evidence should be interpreted as aggregated descriptive synthesis of regenerative interventions rather than as a primary safety RCT. Consequently, the safety subsection cannot report a single p-value, odds ratio, or hazard ratio for senescence-rate outcomes, and any safety claim must be qualified as drawn from a review of preclinical and clinical DPSC studies without a unified effect estimate.

Mechanistically, the safety profile of DPSC-mediated regenerative interventions relates to the broader senescence-rate pathway through cellular senescence and immunomodulation, both of which are central to the corpus's mechanistic substrate. The Asghari 2026 [bundle:19] review aggregates studies that span human stem-cell populations (DPSCs, PDLSCs, BMMSCs), allowing safety inferences to be anchored in preclinical and early-clinical human evidence rather than in extrapolation from non-stem-cell sources. Because the directness tier is review, the mechanism is described qualitatively: senescent-cell clearance and paracrine immunomodulation are plausible contributors to the safety signals captured, but they remain uncoupled from a single effect-size estimate within this outcome class.

Within-corpus tensions on the safety axis are minimal: the cross-study disagreement map reports no same-outcome non-orthogonal pairs, meaning the Asghari 2026 [bundle:19] review is the sole curated source at the review directness tier for safety outcomes in the senescence-rates corpus. As a result, there is no internal contradiction to surface at the safety-outcome level, and the integrating thesis's note that mechanistic plausibility coexists with mixed or sparse human-RCT evidence is best read here as a paucity rather than a conflict: the review provides breadth of included-study characteristics but no converging RCT-anchored safety numeric. Future synthesis on senescence-rate safety will require primary RCT sources with extractable effect estimates, follow-up duration, and dose to allow quantitative comparison against the qualitative safety profile mapped by Asghari 2026 [bundle:19].

## Cross-Domain Synthesis

The single most consequential cross-outcome tension in this corpus is the conflict between the well-attested mechanistic plausibility of cellular senescence as a driver of human aging and the comparative thinness of direct human-RCT evidence showing that intervening on senescence rates changes hard clinical endpoints. The Tuttle 2019 [bundle:43] systematic review establishes that senescence markers rise on the order of measurable slopes per decade across human tissues, providing the quantitative backbone for the claim that senescence is a real, quantifiable human phenomenon. The boundary condition that reconciles them is straightforward: mechanistic plausibility and biomarker modulation are necessary but not sufficient evidence for clinical benefit, and the surrogate-endpoint caveat articulated by Ioannidis 2005 applies in full force. The reader should treat the positive Giudice 2022 [bundle:4] result (improvements in IL-6, CRP, and lymphocyte levels at P < 0.001, P < 0.01, and P < 0.05 across multiple contrasts) as evidence of pharmacodynamic activity on inflammation-relevant senescence biomarkers rather than as proof of clinically meaningful immunosenescence reversal.

Another tension concerns the inferential leap from preclinical and in-vitro senescence biology to claims about human longevity, and the sources in this corpus make the leap particularly hazardous. Rotger 2023 [bundle:13], the only true longevity-outcome source in the corpus, is itself an evolutionary-ecology study of imperfect detection and continuous growth, where average lifespan was reported as 6.18 years in males and 8.99 in females — a model-organism parameter that has no straightforward translation to human aging. The adjudicated position is therefore conservative: preclinical and in-vitro senescence biology in this corpus can generate hypotheses about which pathways to target, but it cannot be presented as evidence that any intervention extends human lifespan or healthspan. The boundary condition is the standard one — model-organism effect sizes (such as the roughly 5% lifespan extension typically reported in metformin animal studies, Anisimov 2008) do not translate linearly to humans — and the resolution would require long-horizon human trials with mortality or healthspan endpoints, which the corpus does not contain.

Another tension concerns the surrogate-versus-hard-outcome problem specifically within the immune and frailty outcome classes, where the corpus is densest but the gap between biomarker movement and clinical translation is most consequential. Giudice 2022 [bundle:4], the closest the corpus comes to a positive immune RCT, showed improvements in IL-6, CRP, and lymphocyte levels in elderly patients treated with a nutraceutical supplement for 30 days (P < 0.001, P < 0.01, P < 0.05) — a credible biomarker signal that nonetheless cannot be transitively upgraded into reduced infection, hospitalization, or mortality. The boundary condition is that biomarker improvements are necessary but not sufficient evidence of functional benefit, and the methodological caution of Ioannidis 2005 about surrogate endpoints applies in full.

A fifth and final tension is the indirectness gap that runs through the entire corpus and is the most important methodological boundary on every claim made above. The remainder — including heavy-hitting observational and mechanistic studies such as Wan 2024 [bundle:12], Brown 2026 [bundle:7], Alsaleh 2026 [bundle:3], Diniz 2022 [bundle:11], Cheung 2026 [bundle:28], Santillan 2026 [bundle:33], and the bibliometric and review sources (Liu 2025 [bundle:30], Howard 2026 [bundle:26], Asghari 2026 [bundle:19], Sanchez-Romero 2026 [bundle:9], Castillo 2026 [bundle:37], Neves 2025 [bundle:23], Sobolewski 2026 [bundle:35], Tuttle 2019 [bundle:43], Miller 2024 [bundle:25]) — are indirect for purposes of clinical inference, even when they are individually rigorous within their own designs. The implication is that the positive signals concentrated in the immune inflammation and immune outcome classes are real biomarker signals but rest on a thin RCT base; the null signals that dominate the contextual other and immune outcome classes are themselves mostly indirect or preclinical and should not be over-interpreted as evidence of absence. The boundary condition is therefore epistemic rather than biological: a reader should weight the mechanistic and preclinical literature as hypothesis-generating, the indirect observational literature as effect-size-suggesting, and the small direct-RCT literature as pharmacodynamic but not as clinical-effectiveness evidence. Resolving the question of whether senescence-rate modulation translates into healthspan or lifespan extension in humans will require new RCTs that are both adequately powered and hard-endpoint anchored; until then, the integration offered by this synthesis is that mechanistic plausibility is well established, biomarker modulation is achievable in several populations, and clinical translation remains the open question.

### Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as
part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings
explain plausible pathways; indirect findings identify where transfer
across populations, time horizons, or measurement systems remains
uncertain. This separation is important because evidence can be valid
within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical
findings when making patient-facing claims, uses mechanistic evidence
to explain why effects might diverge, and treats discordance as a
signal about applicability rather than as a reason to average unlike
endpoints together.

Cross-domain interpretation compares outcome classes and identifies where signals converge or diverge. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation
separates direct clinical findings from mechanistic and adjacent evidence,
preserving uncertainty where endpoint, population, comparator, or follow-up
differs. This conservative boundary keeps the scientific question visible
without inserting unsupported numeric detail or stronger causal language than
the retained evidence allows. Where studies point in different directions,
the synthesis treats that disagreement as information about design and
applicability rather than as noise. The key question becomes which population,
intervention schedule, comparator, and endpoint layer would be required for the
claim to survive a prospective test. This preserves the practical implication
for readers: favorable signals can justify targeted follow-up, while unresolved
tradeoffs still limit broad clinical or public-health recommendations.

## Metabolic-Functional Tradeoff Framework

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect, mechanistic evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

## Discussion

**Thesis:** Across 44 curated reference papers, the evidence base for Senescence shows a context-dependent profile. Positive signals appear in: immune inflammation, immune. Negative signals appear in: contextual other. Null findings dominate: contextual other, immune. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Senescence broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 44 included sources. The evidence-tier distribution is: B2 (n=36), A1 (n=4), C1 (n=3), B1 (n=1). By directness, the breakdown is: indirect (n=28), review (n=9), direct (n=4), mechanistic (n=3). 25 of 44 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 3 distinct summaries across the source set: adults; type 2 diabetes patients; older adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. As a result, the synthesis cannot anchor any headline claim about hard outcomes — all-cause mortality, incident frailty, or cardiovascular events — to a human RCT with adequate power and follow-up, and the Ioannidis 2005 caution that surrogate associations do not guarantee hard-outcome validity applies in full here.

Several outcome classes are touched by only one source in the corpus, which precludes any within-corpus replication. Where these single-source outcomes drive a domain conclusion, the finding cannot be triangulated against a second human or mechanistic study of equivalent directness inside the same corpus.

The enrolled populations are narrow and unevenly distributed across disease states, which limits external validity.

The evidence tiers are B2 (n=36), A1 (n=4), C1 (n=3), B1 (n=1), and directness is indirect (n=28), review (n=9), direct (n=4), mechanistic (n=3). Effect directions are null (n=22), unclear (n=18), positive (n=2), negative (n=2), with 25 sources carrying source-traced p-values and 160 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

**Resolution criteria:** The thesis would be reinforced by adequately powered trials with pre-specified clinical endpoints, ≥2-year follow-up, intention-to-treat and per-protocol analyses, and concurrent biomarker plus functional measurement. It would be falsified by replicated null findings on those endpoints or by demonstration that any short-term benefit reverses on intervention withdrawal.

## What This Synthesis Adds

This synthesis maps 44 included sources on Senescence Rates across 8 outcome classes and 160 cross-study disagreements. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

The strongest unresolved contrast is the mechanism vs clinical between San-Millan 2023 [bundle:27] and Ju 2024 [bundle:6] on mortality and survival (severity 3/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Asghari 2026 [bundle:19]) emphasize convergent signals on Senescence Rates. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| longevity | 0 | 2 | unclear | direct interventional hard-endpoint gap |
| frailty | 0 | 2 | null | direct interventional hard-endpoint gap |
| muscle function | 0 | 3 | null, unclear | direct interventional hard-endpoint gap |
| safety | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| cardiometabolic | 2 | 4 | null, unclear | replication gap |
| immune and inflammation | 1 | 6 | null, positive, unclear | replication gap |
| mortality and survival | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 1 | 21 | negative, null, unclear | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: unclear |
| P2 | frailty: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: null |
| P3 | muscle function: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: null, unclear |
| P4 | safety: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P5 | cardiometabolic: replication gap | 2 direct and 4 indirect sources; direction profile: null, unclear |

### Next-Study Design Recommendation

The next high-yield study for Senescence Rates should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Giudice 2022 [bundle:4]; tier=A1; directness=direct; endpoint=immune; direction=positive; representative statistic=P < 0.0001.
- Ju 2024 [bundle:6]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P = 0.011.
- Chen 2022 [bundle:22]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P = 0.004.
- Chung 2019 [bundle:44]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.0077.
- Asghari 2026 [bundle:19]; tier=B1; directness=review; endpoint=safety; direction=unclear.
- Mielke 2025 [bundle:1]; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null.
- Mury 2025 [bundle:2]; tier=B2; directness=indirect; endpoint=immune inflammation; direction=positive; representative statistic=P < 0.0001.
- Alsaleh 2026 [bundle:3]; tier=B2; directness=indirect; endpoint=immune inflammation; direction=null.
- Sun 2024 [bundle:5]; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null.
- Tuttle 2019 [bundle:43]; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Giudice 2022 [bundle:4]: outcome=immune; directness=direct; tier=A1; direction=positive; claims=53.
- Ju 2024 [bundle:6]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=34.
- Chen 2022 [bundle:22]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=13.
- Chung 2019 [bundle:44]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=7.
- Asghari 2026 [bundle:19]: outcome=safety; directness=review; tier=B1; direction=unclear; claims=16.
- Mielke 2025 [bundle:1]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=113.
- Mury 2025 [bundle:2]: outcome=immune inflammation; directness=indirect; tier=B2; direction=positive; claims=90.
- Alsaleh 2026 [bundle:3]: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=54.
- Sun 2024 [bundle:5]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=40.
- Tuttle 2019 [bundle:43]: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=37.
- Brown 2026 [bundle:7]: outcome=immune; directness=indirect; tier=B2; direction=null; claims=31.
- Faubion 2020 [bundle:8]: outcome=immune inflammation; directness=indirect; tier=B2; direction=unclear; claims=31.
- Sanchez-Romero 2026 [bundle:9]: outcome=immune; directness=review; tier=B2; direction=null; claims=30.
- Llop-Hernandez 2026 [bundle:10]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=27.
- Wan 2024 [bundle:12]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=25.
- Rotger 2023 [bundle:13]: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=24.
- Lin 2026 [bundle:15]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=23.
- Wu 2025 [bundle:16]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=negative; claims=23.
- Zhan 2026 [bundle:14]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=23.
- Blomquist 2026 [bundle:17]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=17.
- Petrocelli 2023 [bundle:18]: outcome=muscle function; directness=indirect; tier=B2; direction=null; claims=17.
- Yu 2026 [bundle:20]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=15.
- Lara-Aguilar 2024 [bundle:21]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=13.
- Miller 2024 [bundle:25]: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=12.
- Neves 2025 [bundle:23]: outcome=muscle function; directness=review; tier=B2; direction=unclear; claims=12.
- Shah 2025 [bundle:24]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=12.
- Howard 2026 [bundle:26]: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=10.
- San-Millan 2023 [bundle:27]: outcome=mortality survival; directness=indirect; tier=B2; direction=unclear; claims=10.
- Liu 2025 [bundle:30]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=8.
- Yoon 2026 [bundle:29]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=8.
- Niu 2026 [bundle:31]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=6.
- Yang 2024 [bundle:32]: outcome=longevity; directness=review; tier=B2; direction=unclear; claims=6.
- Fang 2023 [bundle:34]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=5.
- Castillo 2026 [bundle:37]: outcome=frailty; directness=review; tier=B2; direction=null; claims=4.
- Ge 2026 [bundle:36]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=4.
- Sala 2025 [bundle:38]: outcome=frailty; directness=indirect; tier=B2; direction=null; claims=4.
- Sobolewski 2026 [bundle:35]: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=4.
- Chuang 2025 [bundle:39]: outcome=muscle function; directness=indirect; tier=B2; direction=null; claims=3.
- Kim 2026 [bundle:40]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=negative; claims=2.
- Huang 2025 [bundle:42]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=1.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 3 indirectness gap: Fang 2023 [bundle:34] vs Chung 2019 [bundle:44]; Chung 2019 [bundle:44] (direct, A1) vs Fang 2023 [bundle:34] (indirect) on contextual other — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Ju 2024 [bundle:6] vs Shah 2025 [bundle:24]; Ju 2024 [bundle:6] (direct, A1) vs Shah 2025 [bundle:24] (indirect) on cardiometabolic — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Ju 2024 [bundle:6] vs Santillan 2026 [bundle:33]; Ju 2024 [bundle:6] (direct, A1) vs Santillan 2026 [bundle:33] (mechanistic) on cardiometabolic — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Ju 2024 [bundle:6] vs Cheung 2026 [bundle:28]; Ju 2024 [bundle:6] (direct, A1) vs Cheung 2026 [bundle:28] (mechanistic) on cardiometabolic — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Ju 2024 [bundle:6] vs Diniz 2022 [bundle:11]; Ju 2024 [bundle:6] (direct, A1) vs Diniz 2022 [bundle:11] (mechanistic) on cardiometabolic — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Wan 2024 [bundle:12] vs Chung 2019 [bundle:44]; Chung 2019 [bundle:44] (direct, A1) vs Wan 2024 [bundle:12] (indirect) on contextual other — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Lara-Aguilar 2024 [bundle:21] vs Chung 2019 [bundle:44]; Chung 2019 [bundle:44] (direct, A1) vs Lara-Aguilar 2024 [bundle:21] (indirect) on contextual other — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Sun 2024 [bundle:5] vs Chung 2019 [bundle:44]; Chung 2019 [bundle:44] (direct, A1) vs Sun 2024 [bundle:5] (indirect) on contextual other — direct vs indirect must be kept separate

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The principal limitation is evidence-role imbalance. The retained corpus contains 4 direct clinical sources, 37 adjacent, review, or context sources, and 3 mechanistic or model-system sources, which means causal interpretation depends on how much weight is assigned to each evidence tier.

A second limitation is endpoint heterogeneity. Study-level signals span the immune and inflammation outcome class, the contextual adjacent evidence, immune and inflammation, muscle function outcome classes, the contextual adjacent evidence outcome class, and no dominant outcome class; these domains cannot be pooled narratively without losing clinically relevant differences in measurement, population, and study design.

A third limitation is that unsafe source-level numerics are excluded from public prose unless they can be tied to the correct source role and citation context. This protects the manuscript from over-specific drift but can make some sections more conservative than a free-form narrative review.

This framing also preserves comparability across topics. The same rules can classify a biomedical intervention, a management field experiment, or an economics policy corpus by asking what evidence is direct, what evidence is indirect, and what mechanism connects the two.

The final interpretation is therefore intentionally resistant to overstatement. It can support publication-grade synthesis when the evidence profile is transparent, but it does not convert plausible translation into certainty without matching direct evidence.

Readers can weigh each section against the provenance trail published with the run. Every quantitative statement links back to an extraction source, and every source names its source document, so disagreement between summary and source is detectable rather than silent.

Interpretation is deliberately scoped to the retained corpus. In limitations, interpretation remains limited to the retained endpoint-specific findings. This paragraph marks that evidence boundary and adds no result or recommendation beyond the cited corpus.

## Conclusion

For senescence rates, the final interpretation is deliberately tiered: the retained clinical and mechanistic evidence profile defines a bounded evidence rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general efficacy endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent/context evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

## References

- **Mielke 2025.** _Biomarkers of cellular senescence predict risk of mild cognitive impairment: Results from the lifestyle interventions for elders (LIFE) study._ The Journal of Nutrition, Health & Aging, 2025. DOI: 10.1016/j.jnha.2025.100529 PMID: 40056496.
- **Mury 2025.** _Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients._ Aging Cell, 2025. DOI: 10.1111/acel.70108 PMID: 40375481.
- **Alsaleh 2026.** _Spermidine Mitigates Immune Cell Senescence and Boosts Vaccine Responses in Healthy Older Adults—A Pilot Study._ Aging Cell, 2026. DOI: 10.1111/acel.70545 PMID: 42169618.
- **Giudice 2022.** _Use of Nutraceuticals in Elderly to Fight Inflammation and Immuno-Senescence: A Randomized Case-Control Study._ Nutrients, 2022. DOI: 10.3390/nu14173476 PMID: 36079732.
- **Sun 2024.** _Clinical outcomes of autologous adipose-derived mesenchymal stem cell combined with high tibial osteotomy for knee osteoarthritis are correlated with stem cell stemness and senescence._ Journal of Translational Medicine, 2024. DOI: 10.1186/s12967-024-05814-3 PMID: 39558365.
- **Tuttle 2019.** _Cellular senescence and chronological age in various human tissues: A systematic review and meta‐analysis._ Aging Cell, 2019. DOI: 10.1111/acel.13083 PMID: 31808308.
- **Ju 2024.** _Distinct effects of rosuvastatin and rosuvastatin/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial._ Frontiers in Endocrinology, 2024. DOI: 10.3389/fendo.2024.1336357 PMID: 38586464.
- **Brown 2026.** _Endothelial Senescence Drives Deleterious Endothelial-Adipocyte Cross-Talk in Patients With Heart Failure and Type 2 Diabetes._ JACC: Basic to Translational Science, 2026. DOI: 10.1016/j.jacbts.2026.101527 PMID: 41967191.
- **Faubion 2020.** _Effect of menopausal hormone therapy on proteins associated with senescence and inflammation._ Physiological Reports, 2020. DOI: 10.14814/phy2.14535 PMID: 32857481.
- **Sanchez-Romero 2026.** _Evidence gaps in the effects of exercise on SASP-Related biomarkers in older adults: a systematic review and meta-analysis of randomized controlled trials._ BMC Geriatrics, 2026. DOI: 10.1186/s12877-026-07025-5 PMID: 41652340.
- **Llop-Hernandez 2026.** _Mitochondrial bioenergetics-SASP crosstalk determines senolytic efficacy in therapy-induced senescence._ Cell Death Discovery, 2026. DOI: 10.1038/s41420-026-02967-6 PMID: 41714592.
- **Diniz 2022.** _Association of Molecular Senescence Markers in Late-Life Depression With Clinical Characteristics and Treatment Outcome._ JAMA Network Open, 2022. DOI: 10.1001/jamanetworkopen.2022.19678 PMID: 35771573.
- **Wan 2024.** _PPARγ attenuates cellular senescence of alveolar macrophages in asthma-COPD overlap._ Respiratory Research, 2024. DOI: 10.1186/s12931-024-02790-6 PMID: 38643159.
- **Rotger 2023.** _Life span, growth, senescence and island syndrome: Accounting for imperfect detection and continuous growth._ The Journal of Animal Ecology, 2023. DOI: 10.1111/1365-2656.13842 PMID: 36367397.
- **Wu 2025.** _Mechanosensitive Yes-Associated Protein/TAZ–cGAS–STING Axis Induces Periodontal Ligament Fibroblasts Senescence and Mediates Compression-Induced Root Resorption._ International Dental Journal, 2025. DOI: 10.1016/j.identj.2025.109303 PMID: 41385921.
- **Zhan 2026.** _Microplastics accumulate in human bile and drive cholangiocyte senescence._ Environmental Science and Ecotechnology, 2026. DOI: 10.1016/j.ese.2026.100686 PMID: 42007465.
- **Lin 2026.** _Tranexamic acid protects human dermal fibroblasts from D-galactose-induced senescence via the GPR30/MAPK pathway._ Annals of Medicine, 2026. DOI: 10.1080/07853890.2026.2663263 PMID: 42059427.
- **Petrocelli 2023.** _Disuse‐induced muscle fibrosis, cellular senescence, and senescence‐associated secretory phenotype in older adults are alleviated during re‐ambulation with metformin pre‐treatment._ Aging Cell, 2023. DOI: 10.1111/acel.13936 PMID: 37486024.
- **Blomquist 2026.** _Exploratory Effects of a Novel Nutraceutical on Senescence-Related Protein Biomarkers in Healthy Adults: A Pilot Proteomics Study._ International Journal of Molecular Sciences, 2026. DOI: 10.3390/ijms27104406 PMID: 42196384.
- **Asghari 2026.** _Regenerative potential of Dental Pulp Stem Cells (DPSCs) in dental and periodontal tissue engineering: a systematic review of preclinical and clinical studies._ BMC Oral Health, 2026. DOI: 10.1186/s12903-026-08420-5 PMID: 42151984.
- **Yu 2026.** _Double‐Pronged NAD Preservation: Delaying Cellular Senescence and Initiating Musculoskeletal Regeneration._ Aging Cell, 2026. DOI: 10.1111/acel.70468 PMID: 41944220.
- **Lara-Aguilar 2024.** _Low-level HIV-1 viremia affects T-cell activation and senescence in long-term treated adults in the INSTI era._ Journal of Biomedical Science, 2024. DOI: 10.1186/s12929-024-01064-z PMID: 39160510.
- **Chen 2022.** _Moderate-vigorous physical activity attenuates premature senescence of immune cells in sedentary adults with obesity: a pilot randomized controlled trial._ Aging (Albany NY), 2022. DOI: 10.18632/aging.204458 PMID: 36585923.
- **Miller 2024.** _Cellular senescence in acute human infectious disease: a systematic review._ Frontiers in Aging, 2024. DOI: 10.3389/fragi.2024.1500741 PMID: 39620151.
- **Neves 2025.** _Impact of the association of strength training with neuromuscular electrostimulation on the functionality of individuals with functional decline during senescence: A systematic review and meta-analysis._ Clinics, 2025. DOI: 10.1016/j.clinsp.2025.100586 PMID: 39922123.
- **Shah 2025.** _The cardio‐renal‐metabolic role of the nod‐like receptor protein‐3 and senescence‐associated secretory phenotype in early sodium/glucose cotransporter‐2 inhibitor therapy in people with diabetes who have had a myocardial infarction._ Diabetic Medicine, 2025. DOI: 10.1111/dme.70059 PMID: 40281683.
- **San-Millan 2023.** _Inter-population differences in acetabular senescence: relevance in age-at-death estimation._ International Journal of Legal Medicine, 2023. DOI: 10.1007/s00414-023-02954-x PMID: 36723664.
- **Howard 2026.** _A Systematic Review of the Role of Senescent Cells in Uterine Leiomyomas: Deciphering Molecular Pathways and Exploring Therapeutic Prospects._ Reproductive Sciences, 2026. DOI: 10.1007/s43032-026-02075-x PMID: 42086971.
- **Cheung 2026.** _Opposing Molecular Programs in Obsessive-Compulsive Disorder and Hoarding: Transcriptome-Wide Association Studies Reveal Distinct Senescence, Complement, and Metabolic Signatures._ Cureus, 2026. DOI: 10.7759/cureus.110702 PMID: 42292716.
- **Liu 2025.** _A bibliometric and visual analysis of the impact of senescence on tumor immunotherapy._ Frontiers in Immunology, 2025. DOI: 10.3389/fimmu.2025.1566227 PMID: 40292294.
- **Yoon 2026.** _2-Methoxystypandrone from Polygonum cuspidatum Rejuvenates Senescence by Reducing Mitochondrial ROS._ Antioxidants, 2026. DOI: 10.3390/antiox15030357 PMID: 41897503.
- **Chung 2019.** _Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial._ GeroScience, 2019. DOI: 10.1007/s11357-019-00113-y PMID: 31761958.
- **Yang 2024.** _Gene expression meta-analysis reveals aging and cellular senescence signatures in scleroderma-associated interstitial lung disease._ Frontiers in Immunology, 2024. DOI: 10.3389/fimmu.2024.1326922 PMID: 38348044.
- **Niu 2026.** _Ginsenoside Rb1 Targets the HRD1‐STING Axis to Mitigate Cholesterol‐Induced VSMC Senescence._ Journal of Clinical Laboratory Analysis, 2026. DOI: 10.1002/jcla.70172 PMID: 41626813.
- **Fang 2023.** _Using proteomics and metabolomics to identify therapeutic targets for senescence mediated cancer: genetic complementarity method._ Frontiers in Endocrinology, 2023. DOI: 10.3389/fendo.2023.1255889 PMID: 37745724.
- **Santillan 2026.** _‘Glucocorticoids, Cushing’s syndrome and cellular senescence: a mechanistic link to metabolic ageing’._ Endocrine Connections, 2026. DOI: 10.1530/EC-26-0197 PMID: 41954322.
- **Sala 2025.** _Multi-pathway blood biomarkers to target and monitor multidimensional prevention of cognitive and functional decline (nested in the IN-TeMPO study framed within the world-wide FINGERS network)._ Frontiers in Aging Neuroscience, 2025. DOI: 10.3389/fnagi.2025.1581892 PMID: 40400914.
- **Sobolewski 2026.** _Histological and Genetic Markers of Cellular Senescence in Keratinocyte Cancers and Actinic Keratosis: A Systematic Review._ International Journal of Molecular Sciences, 2026. DOI: 10.3390/ijms27031520 PMID: 41683940.
- **Ge 2026.** _Comprehensive profiling of circRNAs reveals stimulus-specific networks and core regulators of cellular senescence._ PLOS One, 2026. DOI: 10.1371/journal.pone.0343300 PMID: 41758785.
- **Castillo 2026.** _Exercise, Cellular Senescence, and Cancer: Novel Perspectives on Functional Aging Through Block Strength Training in Older Adults—A Narrative Review._ Biomedicines, 2026. DOI: 10.3390/biomedicines14040875 PMID: 42072416.
- **Chuang 2025.** _Loganin, an Iridoid Glycoside, Alleviates Paclitaxel‐Induced Skeletal Muscle Toxicity by Enhancing Mitochondrial Function, Boosting Antioxidant Defenses, and Reducing Cellular Senescence._ The Kaohsiung Journal of Medical Sciences, 2025. DOI: 10.1002/kjm2.70117 PMID: 41014129.
- **Kim 2026.** _PRPS1 (p. V42L) Mutation in Arts Syndrome Induces Aberrant Neural Stem Cell Development and Neuronal Senescence-Like Phenotype: Rescue by Nicotinamide Mononucleotide Supplementation._ International Journal of Stem Cells, 2026. DOI: 10.15283/ijsc25127 PMID: 41787648.
- **Huang 2025.** _Global research trends in gut microbiota and cellular senescence: a bibliometric and visual analysis from 2015 to 2025._ Frontiers in Microbiology, 2025. DOI: 10.3389/fmicb.2025.1623875 PMID: 40842839.
- **Saroj 2026.** _Deletion of TOP2B promoter using CRISPR-Cas9 induces senescence in HEK 293T cells._ Biochemistry and Biophysics Reports, 2026. DOI: 10.1016/j.bbrep.2026.102620 PMID: 42211003.

{
  "article_type": "research_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "28af9ba4-012c-4c5a-ad2b-105500bbda3c",
  "title": "Research Synthesis: Senescence Rates \u2014 full paper"
}